Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vaccinia virus-inoculated rabbit skin extract
- Development stage
- Phase 3
- Lead developer
- Nippon Zoki Pharmaceutical
- Administration
- Intravenous, Intramuscular, Oral
01
Overview
Vaccinia virus-inoculated rabbit skin extract is a biological analgesic and anti-inflammatory agent derived from the skin of rabbits that have been inoculated with the vaccinia virus. It is primarily utilized for the management of chronic pain conditions, including lumbago (low back pain), neuralgia, and post-herpetic neuralgia. The drug's mechanism of action is distinct from traditional NSAIDs or opioids; it primarily works by activating the descending pain inhibitory system, specifically the serotonergic and noradrenergic pathways, which modulate pain transmission in the spinal cord. Additionally, it has been shown to inhibit the release of inflammatory mediators such as bradykinin and provide neuroprotective effects. Originally developed by Nippon Zoki Pharmaceutical, it is also manufactured and marketed by companies like Weishi Pharmaceutical (Rugao) Co., Ltd. in China under the brand name Analgecine.
- Brand names
- AnalgecineNeurotropinEnzelin
- Other names
- Extract of rabbit skin inflamed by vaccinia virusVaccinia virus-inoculated rabbit skin extractVaccinia virus-inflamed rabbit skin extract
Beyond the preview
Go deeper on vaccinia virus-inoculated rabbit skin extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vaccinia virus-inoculated rabbit skin extract.